DCTH - Delcath Systems, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0390
-0.0009 (-2.26%)
At close: 3:42PM EST
Stock chart is not supported by your current browser
Previous Close0.0399
Open0.0399
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0371 - 0.0399
52 Week Range0.0350 - 0.4000
Volume447,219
Avg. Volume232,609
Market Cap857,134
Beta (5Y Monthly)0.04
PE Ratio (TTM)N/A
EPS (TTM)-2.7620
Earnings DateNov 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00
  • GlobeNewswire

    Delcath Systems to Present at the 12th Annual LD Micro Main Event on December 10, 2019

    NEW YORK, Dec. 03, 2019 -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today.

  • GlobeNewswire

    Delcath Systems Announces Postponement of Reverse Stock Split

    Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT) and has been used at major medical centers to treat a wide range of cancers of the liver.

  • GlobeNewswire

    Delcath Systems Announces Ratio for Reverse Stock Split

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’s Board of Directors has authorized a reverse stock split of the Company’s common stock at a ratio of 1-for-100. The Company’s Board of Directors was authorized to effect the reverse stock split by shareholder approval of its Proxy Solicitation filed with the Securities Exchange Commission on August 19, 2019. The proposal to effect a reverse stock split was approved by shareholders on September 17, 2019.

  • ACCESSWIRE

    MicroCap Rodeo - Investor Conference Lineup for October 15 and 16, 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16 th , 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, ...

  • GlobeNewswire

    Delcath Systems to Present at the MicroCap Rodeo Investor Conference

    Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (DCTH) will present at the MicroCap Rodeo. To schedule a one-on-one meeting, please contact your conference representative or James Carbonara at Hayden IR. Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.

  • GlobeNewswire

    Delcath Systems to Participate in Upcoming Investor Conferences

    To schedule a one-on-one meeting, please contact your conference representative or James Carbonara at Hayden IR. Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.

  • ACCESSWIRE

    MicroCap Rodeo Investor Conference - October 15 and 16, 2019, Austin Texas

    Company lineup is filling up fast with 50 good names in the microcap markets, as well as some great private and Pre-IPO companies AUSTIN, TX / ACCESSWIRE / September 19, 2019 / The MicroCap Rodeo's inaugural ...

  • GlobeNewswire

    Delcath Systems Announces Presentation at the Rodman & Renshaw 21st Annual Global Investment Conference sponsored by H.C. Wainwright

    Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (DCTH) will present at the Rodman & Renshaw 21st Annual Global Investment Conference sponsored by H.C. Wainwright, at 5:05pm on Tuesday, September 10, 2019. The conference will be held September 8-10, 2019 at the Lotte New York Palace Hotel. To schedule a one-on-one meeting, please contact your H.C. Wainwright representative or James Carbonara at Hayden IR.

  • GlobeNewswire

    Delcath Systems Closes $9.5 Million Private Placement

    NEW YORK, Aug. 20, 2019 (GLOBE NEWSWIRE) --  Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (DCTH) has closed on its previously announced private placement with gross proceeds of $9.5 million at a combined price of $1,000 per Unit. Each Unit consists of one preferred share initially convertible into 16,667 shares of common stock at an initial conversion price of $0.06 per share and a common stock purchase warrant. Each whole warrant entitles the holder to purchase one share of common stock at an initial exercise price of $0.06 for a period of five years from the date of the Company’s anticipated reverse stock split.

  • GlobeNewswire

    Delcath Systems Announces $9.5 Million Private Placement

    Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (DCTH)) today announced that it has entered into a definitive agreement for gross proceeds of approximately $9.5 million at a combined price of $1,000 per Unit. Each Unit consists of one preferred share initially convertible into 16,667 shares of common stock at an initial conversion price of $0.06 per share and a common stock purchase warrant. Each whole warrant entitles the holder to purchase one share of common stock at an initial exercise price of $0.06 for a period of five years from the date of the Company’s anticipated reverse stock split.

  • GlobeNewswire

    Delcath Enhances Board of Directors With Appointment of Commercial Leader, John R. Sylvester

    Seasoned leader with successful track record joins to help Delcath in the next phase of its development. NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTC Pink: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that John R. Sylvester, a pharmaceutical and medical device executive with a greater than 30-year career focused on growing business, creating markets and implementing commercialization strategies, has joined the Delcath Board of Directors effective July 24, 2019. Mr. Sylvester currently serves as Chief Commercial Officer at BTG PLC, an international specialist healthcare company that develops and commercializes products targeting critical care, cancer and other disorders.

  • GlobeNewswire

    Results of Single Center Study on Delcath’s PHP Therapy Published in Cancer Imaging

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results from a single-institution retrospective study conducted by University Hospital of Tubingen (UHT) in  Germany on the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metastatic ocular melanoma with liver metastases were published in the journal Cancer Imaging.

  • GlobeNewswire

    Delcath Systems Closes $20 Million Private Placement

    Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (DCTH) has closed on its previously announced private placement with gross proceeds of $20 million at a combined price of $1,000 per Unit. Each Unit consists of one preferred share initially convertible into 16,667 shares of common stock at an initial conversion price of $0.06 per share and a common stock purchase warrant. Each whole warrant entitles the holder to purchase one share of common stock at an initial exercise price of $0.06 for a period of five years from the date of the Company’s anticipated reverse stock split.

  • GlobeNewswire

    Delcath Systems Announces $20 Million Private Placement

    Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us”) (DCTH) today announced that it has entered into a definitive agreement for gross proceeds of approximately $20 million at a combined price of $1,000 per Unit. Each Unit consists of one preferred share initially convertible into 16,667 shares of common stock at an initial conversion price of $0.06 per share and a common stock purchase warrant. Each whole warrant entitles the holder to purchase one share of common stock at an initial exercise price of $0.06 for a period of five years from the date of the Company’s anticipated reverse stock split.

  • GlobeNewswire

    Results of Single Center Prospective Study on Delcath’s PHP Therapy Presented at ECIO 2019

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results from a prospective phase 2 study conducted by Leiden University Medical Center (LUMC) in the Netherlands on the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metastatic ocular melanoma with liver metastases were presented at the European Conference on Interventional Oncology (ECIO) annual meeting.

  • GlobeNewswire

    Delcath Joins the Ocular Melanoma Community in Recognizing Rare Disease Day

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, highlights the experiences of patients with ocular melanoma as part of Rare Disease Day®—a global awareness campaign observed each year on February 28th. Delcath sponsors a global Registration clinical trial for Patients with Hepatic Dominant Ocular Melanoma called The FOCUS Trial. “Rare Disease Day is an opportunity for the global healthcare community to recognize the unmet medical needs among patients suffering from orphan diseases,” said Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath.

  • GlobeNewswire

    Delcath Announces Health Authority Approval for CHEMOSAT in Brazil

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company has received medical device approval for the CHEMOSAT® Hepatic Delivery System (CHEMOSAT) from the national health authority in Brazil. The approval of CHEMOSAT as a Class 3 medical device was issued by the Agência Nacional de Vigilância Sanitária (ANVISA), and permits the marketing and utilization of CHEMOSAT under the same percutaneous intra-arterial administration of melphalan hydrochloride to the liver with subsequent extracorporeal filtration of blood indication, as in Europe. To develop Brazilian market access for CHEMOSAT, Delcath intends to align with a local strategic partner.

  • GlobeNewswire

    Delcath Announces Acceptance of Abstract for Oral Presentation at ECIO 2019

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces an abstract from a prospective phase 2 study conducted in the Netherlands of the use of the Delcath Hepatic CHEMOSAT® Delivery System to treat patients with metastatic ocular melanoma with liver metastases, has been accepted for oral presentation and as a poster at the European Conference on Interventional Oncology (ECIO) annual meeting. The abstract, Percutaneous hepatic perfusion with melphalan in patients with unresectable liver metastases from ocular melanoma using the Delcath System's second-generation hemofiltration system: a prospective phase II study, will be presented by T.S. Meijer and M.C. Burgmans, et al of the Leiden University Medical Center in the Netherlands.

  • GlobeNewswire

    Delcath Announces Commercial Licensing Agreement for CHEMOSAT®

    Upfront and Milestone Payments Provide Additional Resources to Advance Clinical Development in the U.S. NEW YORK, Dec. 26, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the company has entered into a definitive licensing agreement for CHEMOSAT® commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac), a privately held, multi-national pharmaceutical company based in Hamburg area, Germany. Founded in 1970, medac specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

  • GlobeNewswire

    Delcath Announces 4th Independent Safety Review of Registration Trial Data for Metastatic Ocular Melanoma: Recommended Continuation with no Trial Modification

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the independent Data Safety Monitoring Board (DSMB) of the Registration trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial) completed another pre-specified review of safety data for treated patients in the trial. In July, the Company announced that it has amended the protocol for the FOCUS trial, which is now enrolling as a single-arm, multi-center open label study. Safety data collected have not been modified as a result of the amendment, and safety data from both the randomized and single-arm protocols will be pooled in any analyses submitted to the Food & Drug Administration as part of a New Drug Application.